A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...
Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a ...
Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ --BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License ...
Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were presented ...
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a Biologics License ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback